Abstract
The anti-CD38 IgG/k antibody Daratumumab is particularly efficient alone or combined with other drugs in multiple myeloma (MM) patients. Long Infusion sched-ules of 4 to 8 hours however to avoid incidence of infusion related reactions (IRR) can reduce patients and health care professional compliance. Splitting of the first dose in two days has already reduced length of the first infusion (4 hours each). Strategies to reduce infusion time have been reported. One study (Barr H, et al., Leuke-mia 2018) showed safety in 28 patients with MM with an infusion time of 90 minutes start-ing from dose >10 in the majority.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call